Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Imaging, Device Groups Weigh In On Physician Pay Reform Bill Draft

This article was originally published in The Gray Sheet

Executive Summary

Imaging equipment makers, represented by MITA, had some encouraging words for physician payment reform discussion draft legislation that includes appropriate-use criteria and targeted prior authorization for advanced imaging, but also some cautionary notes. AdvaMed, meanwhile, was more critical of some provisions in the proposal.

You may also be interested in...



Lawmakers Ease Imaging Provisions In Draft Physician Pay Reform Bill

Senate Finance and House Ways and Means Committee lawmakers issued a revised proposal to overhaul the physician payment sustainable growth rate formula in advance of a Dec. 13 markup. In response to public comment, lawmakers included more restrictions on which imaging services might be subject to appropriate-use criteria requirements.

Draft SGR Repeal Bill Reworks Doc Incentives, Includes Imaging/ECG Appropriateness Criteria

The Senate Finance Committee and House Ways & Means Committee circulated a discussion draft to replace the maligned Medicare sustainable growth rate formula for physician pay with a system that freezes base payments but offers value-based incentives. The bill also calls for mandatory use of appropriateness criteria for advanced imaging and electrocardiogram, and prior authorization in some cases.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel